A temperature-inducible protein module for control of mammalian cell fate William Benman Zikang Huang Lukasz J. Bugaj Nature Methods(2025) Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung ...
CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence of CAR-T cells in vivo. Here, we demonstrate that human CAR-T cel
Compared with second-generation CAR-T cells, GPC3-targeted CAR-T cells overexpressing GLUT1 or AGK exhibited greater CD8T-cell persistence in vivo and better antitumor effects in HCC allograft mouse models. Finally, we revealed that GLUT1 or AGK maintained anti-apoptosis ability in CD8T cells ...
Murine CAR T cells, CAR NK cells, and CAR macrophages can be efficiently generated using mRNA transfection and show different anti-tumor activity in vitro To enable a functional comparison of murine NKG2D CAR immune effector cell in syngeneic orthotopic immunocompetent settings, it was crucial to ...
We constructed a CAR targeting CD276 and demonstrated clear evidence of anti-tumor activity of CD276 CAR-T against many cancer cell lines in vitro. Additionally, we obtained Dash CAR-T by shortening the time of CAR-T preparation within 48–72 h. Notably, our investigations revealed that CD...
Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing global incidence. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown efficacy in relapsed or refractory MM, but it faces resistance due to antigen loss and
Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing global incidence. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown efficacy in relapsed or refractory MM, but it faces resistance due to antigen loss and
Video S1. ROR1-DD CAR-T cells induce severe toxicity in mice by day 4 post-T cell administration due to leaky activity in the OFF state, related to Figure 7 Video S2. SNIP ROR1 CAR-T-treated mice do not exhibit any clinical signs of toxicity in the OFF state, related to Figure 7...
Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a concept-shifting therapy with impressive responses in B cell malignancies. This Review summarizes the current state of the CAR T cell field, focusing on CD19- and B cell maturation antigen-directed CAR T ...
Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials. However, the potential for insertional mutagenesis and genotoxicity of viral vectors is a safety concern, and their cost ...